Aprea Therapeutics (APRE) Total Current Liabilities (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Total Current Liabilities of $5.3 million for Q1 2026, up 57.59% year-over-year from $3.4 million in Q1 2025, and up 91.6% quarter-over-quarter from $2.8 million in Q4 2025.
Aprea Therapeutics (APRE) Total Current Liabilities (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Total Current Liabilities for 9 consecutive years, with $5.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 57.59% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (up 57.59% YoY), while the FY2025 annual figure was $2.8 million, down 17.75% from the prior year.
- Total Current Liabilities advanced to $5.3 million in Q1 2026 per APRE's latest filing, from $2.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $7.7 million in Q2 2022 and bottomed at $2.7 million in Q3 2025.
- Historically, Total Current Liabilities has averaged $4.0 million across 5 years, with a median of $3.6 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities slumped 56.25% — and 2026, when it surged 57.59%.
- Aprea Therapeutics' Total Current Liabilities stood at $3.2 million in 2022, then surged by 37.0% to $4.4 million in 2023, then dropped by 23.36% to $3.4 million in 2024, then fell by 17.75% to $2.8 million in 2025, then soared by 91.6% to $5.3 million in 2026.
- Business Quant data shows APRE's Total Current Liabilities at $5.3 million in Q1 2026, $2.8 million in Q4 2025, and $2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Aprea Therapeutics | 34.28 Mn | 34.28 Mn | - | 3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.09 Mn |
| Mar 31, 2026 | 5.30 Mn |
| Dec 31, 2025 | 2.76 Mn |
| Sep 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 3.17 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Dec 31, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.64 Mn |
| Jun 30, 2024 | 3.09 Mn |
| Mar 31, 2024 | 2.97 Mn |
| Dec 31, 2023 | 4.39 Mn |
| Sep 30, 2023 | 4.17 Mn |
| Jun 30, 2023 | 3.95 Mn |
| Mar 31, 2023 | 4.23 Mn |
| Dec 31, 2022 | 3.20 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 7.68 Mn |
| Mar 31, 2022 | 6.72 Mn |
| Dec 31, 2021 | 7.32 Mn |
| Sep 30, 2021 | 9.04 Mn |